Medical/Pharmaceuticals

Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

* Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may bring to patients.  * Data from the elacestrant plus capivasertib regimen of the ELEVATE study will be presented underscoring its potential i...

2026-05-25 18:56 8196

THE FUTURE OF MEN'S HEALTH IS MEASURABLE: EMAGENE.LIFE AND ADAM HEALTH PARTNER TO ADVANCE PRECISION LONGEVITY AND FUNCTIONAL MEDICINE

Emagene.life integrates advanced biodata intelligence, functional medicine, and Avio Health AI technology through a strategic collaboration with Adam Health to support measurable male vitality and longevity. KUALA LUMPUR, Malaysia, May 25, 2026 /PRNewswire/ -- Men's health is entering a new era ...

2026-05-25 13:36 6214

/C O R R E C T I O N -- Medtronic plc/

In the news release, "Medtronic Singapore partners with Society of Colorectal Surgeons to strengthen surgical training", issued on May 25 2026 by Medtronic over PR Newswire, we are advised by the company that the caption text accompanying the image, should read "From left to right: Sharon Lew (Se...

2026-05-25 12:43 5420

Most Singaporeans know about LPAs, but only 1 in 3 have made one

New research by SMU highlights a gap in preparedness, socioeconomic disparities and need for stronger public support as Singapore ages SINGAPORE, May 25, 2026 /PRNewswire/ -- A new study by the Singapore Management University (SMU) Centre for Research on Successful Age...

2026-05-25 09:15 4317

From Pakistan to Shanghai: A CAR-T Journey Fighting Relapsed Lymphoma

SHANGHAI, May 25, 2026 /PRNewswire/ -- A 36-year-old Pakistani patient has achieved encouraging early recovery after receiving personalized CAR-T immunotherapy at Jiahui International Cancer Center in Shanghai, following exhausting standard treatments for aggressive recurrent blood cancer. Muham...

2026-05-25 08:41 3543

Informa Markets Puts Bangkok at the Center of Southeast Asia's Pharma Industry, Uniting 400 Exhibitors, Experts from 70 Countries at CPHI South East Asia

The Region's Premier Pharma Exhibition Returns to Bangkok, Elevating Thailand's Role in the ASEAN Pharmaceutical Supply Chain BANGKOK, May 24, 2026 /PRNewswire/ -- Informa Markets sets to organise CPHI South East Asia from 8–10 July 2026 at Queen Sirikit National Convention Center under the them...

2026-05-24 13:00 5509

Meet Clicklinks: The Innovation Hub for Original Drug Discovery

SHANGHAI, May 23, 2026 /PRNewswire/ -- For many participants in the innovative drug discovery arena, AI-STAL and SAI-DA are already familiar names within the Sanyou Bio ecosystem. AI-STAL is recognized as the "Grand Master Librarian" safeguarding a Super Trillion Antibody Library, while SAI-DA is...

2026-05-23 22:00 5831

79th World Health Assembly adopts resolution on hemophilia and other bleeding disorders

MONTREAL, May 23, 2026 /PRNewswire/ -- On May 22, 2026, the 79th World Health Assembly unanimously adopted a resolution on Global Action to Advance Health Equity for People with Hemophilia and Other Bleeding Disorders. This is a historic development for our community and will help increase diagno...

2026-05-23 02:00 6225

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

EPLive 2026 is a two-day conference that draws the world's top cardiac electrophysiology experts AUSTIN, Texas, May 22, 2026 /PRNewswire/ -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its eighth international symposium on complex arrhythmias on May 28-2...

2026-05-22 21:08 6305

Gene Solutions Showcases AI-Powered Multi-Omics Liquid Biopsy Innovations at TJCC 2026: Advancing Precision Oncology in Taiwan

Satellite symposium and exhibition engagement highlighted strong physician interest in MRD, MCED, and evidence-driven adoption of genomic testing. TAIPEI, May 22, 2026 /PRNewswire/ -- Gene Solutions , an innovative global biotechnology company advan...

2026-05-22 14:45 8703

Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations

SHANGHAI, May 21, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present multiple clinical study results of its novel Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin, BFv) at the 2026 American S...

2026-05-22 11:30 11572

Nuance Pharma Announces IND Clearance for Actair® Pivotal Clinical Trial in China

NMPA Approval Marks Key Milestone in Advancing House Dust Mite Allergy Immunotherapy to Chinese Patients SHANGHAI, May 22, 2026 /PRNewswire/ -- Nuance Pharma today announced that the National Medical Products Administration (NMPA) has cleared its Investigational New Drug (IND) application, enabl...

2026-05-22 09:50 5660

Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026

* Sacituzumab tirumotecan (sac-TMT)(佳泰莱®) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive advanced NSCLC: Results from the randomized, controlled, registrational Phase III OptiTROP-Lung05 study (Abstract #8506) * Efficacy and safety of lunbotinib fumarate (A...

2026-05-22 08:00 9368

Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting

TAIPEI, May 21, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. announces that its abstract highlighting the differentiated binding profile and preclinical efficacy ofTSY-310, a novel bispecific antibody-drug conjugate (ADC), has been selected for presentation at the American Society of Clinic...

2026-05-22 05:34 5436

Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS

CHENGDU, China, May 21, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Breast03) of the Company's tropho...

2026-05-21 22:08 11402

Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL

Head-to-Head Study Highlights Rocbrutinib as the World's First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations GUANGZHOU, China and SAN FRANCISCO, May 21, 2026 /PRNewswire/ -- Lupeng Pharmaceutical Ltd, a global clinical-stage biopharmaceu...

2026-05-21 22:00 7895

Neurophet Appoints Globally Renowned Imaging AI Expert Dr. Lawrence N. Tanenbaum as Scientific Advisor

* Former Vice President and Chief Technology Officer of RadNet, one of the largest outpatient imaging providers in the United States * Appointment expected to strengthen clinical validation, global expansion, and competitiveness in neuroimaging AI SEOUL, South Korea, May 21, 2026 /PRNewswire/...

2026-05-21 21:00 9160

Wincomm Secures Computex Best Choice Award for Three Consecutive Years (2024-2026), Leading the Future of AI-Powered Medical Solutions

HSINCHU, May 21, 2026 /PRNewswire/ -- Wincomm Corporation, a global leader in medical and industrial computing, is proud to announce it has achieved a prestigious milestone by winning the Computex Best Choice Award (BC Award) for three consecutive years from 2024 to 2026. This hat-trick of accola...

2026-05-21 15:16 5092

Singapore Court of Appeal Notes No Finding of Fraud Against KBP or Dr. Huang; Dispute with Novo Nordisk Undergoing Arbitration Proceedings

SINGAPORE, May 21, 2026 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company " or "KBP") today issued a statement addressing the decision by the Singapore Court of Appeal to maintain the temporary injunction against the Company and its founder, Dr. Huang Zhenhua ("Dr. Huang"), pending final res...

2026-05-21 08:52 11545

Hyundai Bioscience Discloses XAFTY®'s IC50 Data for Ebola--"Secured Scientific Evidence for Immediate Treatment"

* Ebola IC50 (0.125μM)—Strong inhibition at less than half the concentration of the clinically-tested COVID-19 (0.28μM). * Clinical safety confirmed through COVID-19 and Dengue clinical trials. * Class-wide efficacy proven by accumulated research data for Hantavirus treatment. * Davey Smit...

2026-05-21 08:38 5667
1 ... 50515253545556 ... 643